Status:
COMPLETED
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated...
Eligibility Criteria
Inclusion
- Adult Thai male or female patients aged greater than or equal to (≥) 18 years.
- Diagnosed with T2D either through International Classification of Diseases (ICD) code or by physician's description such as documentation in the medical record, and who have not previously been treated with injectable glucose-lowering medication.
- At least one recent or closest Glycated Haemoglobin (HbA1c) test value available and documented less than or equal to 12 weeks prior to the initiation of oral semaglutide.
- Had initiated oral semaglutide for diabetes during the target selection period of April 2022 to December 2023. All required data for collection should already be accessible prior to the initiation of data collection.
- Treated with oral semaglutide for at least 6 months without interruption or discontinuation.
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study (if applicable).
- Participants with any diagnosis of type 1 diabetes (T1D).
- Medical records documenting prior or ongoing treatment with injectable glucose-lowering treatment.
Key Trial Info
Start Date :
September 7 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2024
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT06507475
Start Date
September 7 2024
End Date
December 20 2024
Last Update
December 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maharaj Nakorn Chiang Mai Hospital_Nephrology
Chiang Mai, Thailand, 50200